Description
Recombinant Human SUMO1 Protein (His Tag)(Active) | PKSH030730 | Gentaur US, UK & Europe Disrtribition
Synonyms: Small Ubiquitin-Related Modifier 1; SUMO-1; GAP-Modifying Protein 1; GMP1; SMT3 Homolog 3; Sentrin; Ubiquitin-Homology Domain Protein PIC1; Ubiquitin-Like Protein SMT3C; Smt3C; Ubiquitin-Like Protein;UBL1; SUMO1; SMT3C; SMT3H3; UBL1;DAP1;OFC10;SENP2;SMT3
Active Protein: Active protein
Activity: A DNA sequence encoding the human SUMO1 (AAH66306.1) (Ser 2-Val 101) was expressed, with a polyhistide tag at the N-terminus.
Protein Construction: A DNA sequence encoding the human SUMO1 (AAH66306.1) (Ser 2-Val 101) was expressed, with a polyhistide tag at the N-terminus.
Fusion Tag: N-His
Species: Human
Expressed Host: E.coli
Shipping: This product is provided as lyophilized powder which is shipped with ice packs.
Purity: > 90 % as determined by reducing SDS-PAGE.
Endotoxin: Please contact us for more information.
Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Molecular Mass: 12.4 kDa
Formulation: Lyophilized from sterile 20mM Tris, 500mM NaCl, pH 7.5
Reconstitution: Please refer to the printed manual for detailed information.
Background: Small ubiquitin-like modifier protein (SUMO) modification is a highly dynamic process, catalyzed by SUMO-specific activating (E1), conjugating (E2) and ligating (E3) enzymes, and reversed by a family of SUMO-specific proteases (SENPs). Small ubiquitin-like modifier 1 (SUMO1) is a member of the superfamily of ubiquitin-like proteins. Despite its structural similarity with ubiquitin, SUMO1 does not seem to play any role in protein degradation. SUMO1 plays an important role in modulation of NOX activity required for ROS generation. SUMO1 haploinsufficiency results in cleft lip and palate in animal models. SUMO1 gene variation in human non-syndromic cleft lip with or without cleft palate (NSCLP) development. SUMO-1 may be useful as a novel target for therapy in oral squamous cell carcinoma (SCC) as well as a clinical indicator for tumor recurrence together with Mdm2.
Research Area: N/A
